Pharmaceuticals & Therapeutics

A pivotal FDA meeting moves a novel drug forward for Dementia with Lewy Bodies, a disease with no approved therapies, offering new hope to patients.

Roche's CT-388 posts impressive Phase II results, positioning it as a powerful new rival to Zepbound and Wegovy in the booming obesity drug market.

LuskinOIC honors a pioneer of artificial joints with a new award, celebrating a legacy of innovation and propelling the next wave of orthopaedic discovery.

The acquisition strengthens the independent distributor's hold on the booming plasma therapy market, promising wider access to critical, complex medications.

As US organ donor registrations fall, Southern Legacy of Life achieves its second-best year, saving hundreds through strategic community engagement.

A new COVID-19 drug targets patients who can't take Paxlovid, while a once-a-month pill could revolutionize how we prevent seasonal influenza.

Neurocrine Biosciences begins a Phase 2 trial for a new tardive dyskinesia drug, aiming to build on its market dominance and offer new hope for patients.

Leios Therapeutics partners with BNC Korea, securing a key investment and pathway to Asia's lucrative body contouring market for its 10XB-101 injectable.

A new external bioengineered liver has passed a crucial safety trial, offering a potential lifeline for patients with acute liver failure.

Janux Therapeutics appoints Dr. William Go, a key leader behind YESCARTA®'s approval, as CMO to steer its novel immunotherapy pipeline through critical trials.

Following impressive Phase 2 results, Scancell's novel immunotherapy iSCIB1+ receives FDA clearance for a pivotal trial, offering new hope for patients.

A new partnership aims to accelerate a pipeline of innovative multi-functional fusion proteins, potentially reshaping treatment for cancer and autoimmune disease.

Aja Health inks a deal with Greatway Financial to sell its MyCare Ally program and upgrades its GOeVisit platform for advanced virtual care services.

Flexible Solutions posts modest 2025 revenue gains, but a major strategic shift to food-grade products and new factories sets the stage for a breakout year.

Privo Technologies reports its PRV211 patch was well-tolerated in a key trial, offering a new, localized approach to preventing oral cancer recurrence.

Swiss biotech GeNeuro suspends trading, awaiting a critical court ruling on its debt moratorium that will decide its fate and the future of its novel drugs.

As Embecta prepares its Q1 results, investors watch closely to see if its move beyond insulin can reverse recent revenue declines and reshape its future.

A new telehealth pharmacy offers flat-rate annual pricing for compounded weight loss drugs, challenging high costs but raising questions about regulation.

PAQ Therapeutics advances its pan-KRAS degrader into human trials, backed by a $77M funding round, offering new hope for notoriously tough cancers.

With demand soaring, diagnostics leader PreludeDx hires veteran MiMi Reyes to scale lab operations and spearhead the launch of its new AidaBreast test.